Company intelligence / Profile preview

PMD Group

Vancouver, British Columbia, Canada

Ownership: Private
Development stage: Other

Overview

PMD-026 demonstrated favorable tolerability in Phase 1/1b as a monotherapy with median progression-free survival of 4.8 months in RSK2-high metastatic breast cancer patients. Phase 2 Dauntless-1 trial initiated in 2025 evaluating PMD-026 + fulvestrant in HR+/HER2-/RSK2-high metastatic breast cancer.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on PMD Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMD Group.

Explore the full profile